Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Cash from Operations: 2009-2025

Historic Cash from Operations for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $562.1 million.

  • UNITED THERAPEUTICS's Cash from Operations rose 49.02% to $562.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 36.92%. This contributed to the annual value of $1.3 billion for FY2024, which is 35.70% up from last year.
  • Per UNITED THERAPEUTICS's latest filing, its Cash from Operations stood at $562.1 million for Q3 2025, which was up 193.22% from $191.7 million recorded in Q2 2025.
  • In the past 5 years, UNITED THERAPEUTICS's Cash from Operations ranged from a high of $562.1 million in Q3 2025 and a low of $89.8 million during Q1 2021.
  • Its 3-year average for Cash from Operations is $320.0 million, with a median of $346.2 million in 2023.
  • Per our database at Business Quant, UNITED THERAPEUTICS's Cash from Operations crashed by 58.15% in 2021 and then surged by 221.49% in 2022.
  • Quarterly analysis of 5 years shows UNITED THERAPEUTICS's Cash from Operations stood at $174.6 million in 2021, then declined by 26.58% to $128.2 million in 2022, then climbed by 17.55% to $150.7 million in 2023, then spiked by 126.41% to $341.2 million in 2024, then surged by 49.02% to $562.1 million in 2025.
  • Its Cash from Operations was $562.1 million in Q3 2025, compared to $191.7 million in Q2 2025 and $461.2 million in Q1 2025.